Sapha Barkati1, Simon F Dufresne2, Sylvie Bélanger3, Barbara Vadnais4, Julie Bergeron5, Annie Claude Labbé2, Michel Laverdière2. 1. Department of Microbiology and Immunology, Faculty of Medicine, Université de Montréal, Montréal, Que. 2. Department of Microbiology and Immunology, Faculty of Medicine, Université de Montréal, Montréal, Que. ; Department of Microbiology and Infectious Diseases, Hôpital Maisonneuve-Rosemont, Montréal, Que. 3. Department of Microbiology and Infectious Diseases, Hôpital Maisonneuve-Rosemont, Montréal, Que. 4. Department of Pharmacy, Hôpital Maisonneuve-Rosemont, Montréal, Que. ; Faculty of Pharmacy, Université de Montréal, Montréal, Que. 5. Department of Hematology, Hôpital Maisonneuve-Rosemont, Montréal, Que. ; Department of Hematology, Faculty of Medicine, Université de Montréal, Montréal, Que.
Abstract
BACKGROUND: The decision to use universal primary antimould prophylaxis to prevent invasive aspergillosis in patients with acute leukemia depends on the incidence of infection at individual centres. We determined our institution's incidence of invasive aspergillosis among patients who received remission-induction chemotherapy for acute leukemia to evaluate the potential benefits of primary antimould prophylaxis. METHODS: We conducted this retrospective cohort study at a Canadian tertiary care centre. From the central pharmacy registries, we retrieved records for all adult patients for whom remission-induction chemotherapy for acute leukemia was prescribed between 2008 and 2010. We retrieved clinical, microbiologic, pathologic and radiologic data from the patients' medical charts. The primary outcome was a diagnosis of probable or proven invasive aspergillosis up to 180 days after resolution of aplasia. RESULTS: We retrieved records for 123 patients with acute leukemia. Twenty-two of these patients did not receive the prescribed chemotherapy and were excluded from the analysis. Of the 101 patients included, 77 (76.2%) had acute myeloid leukemia. Overall, 136 courses of chemotherapy were administered, with more than 1 course administered to 26 (25.7%) of the 101 patients. In 9 of the patients (8.9%; 95% confidence interval 4.2%-16.2%), invasive aspergillosis was diagnosed (3 proven and 6 probable cases) a median of 19 (range 11-34) days after initiation of chemotherapy. In 7 (78%) of these 9 patients, invasive aspergillosis occurred during the first course of chemotherapy. Three patients died within the first year after diagnosis of invasive aspergillosis. INTERPRETATION: We found a high incidence (8.9%) of invasive aspergillosis at our centre. This finding triggered the introduction of targeted antimould prophylaxis for patients with acute leukemia who were undergoing remission-induction chemotherapy.
BACKGROUND: The decision to use universal primary antimould prophylaxis to prevent invasive aspergillosis in patients with acute leukemia depends on the incidence of infection at individual centres. We determined our institution's incidence of invasive aspergillosis among patients who received remission-induction chemotherapy for acute leukemia to evaluate the potential benefits of primary antimould prophylaxis. METHODS: We conducted this retrospective cohort study at a Canadian tertiary care centre. From the central pharmacy registries, we retrieved records for all adult patients for whom remission-induction chemotherapy for acute leukemia was prescribed between 2008 and 2010. We retrieved clinical, microbiologic, pathologic and radiologic data from the patients' medical charts. The primary outcome was a diagnosis of probable or proven invasive aspergillosis up to 180 days after resolution of aplasia. RESULTS: We retrieved records for 123 patients with acute leukemia. Twenty-two of these patients did not receive the prescribed chemotherapy and were excluded from the analysis. Of the 101 patients included, 77 (76.2%) had acute myeloid leukemia. Overall, 136 courses of chemotherapy were administered, with more than 1 course administered to 26 (25.7%) of the 101 patients. In 9 of the patients (8.9%; 95% confidence interval 4.2%-16.2%), invasive aspergillosis was diagnosed (3 proven and 6 probable cases) a median of 19 (range 11-34) days after initiation of chemotherapy. In 7 (78%) of these 9 patients, invasive aspergillosis occurred during the first course of chemotherapy. Three patients died within the first year after diagnosis of invasive aspergillosis. INTERPRETATION: We found a high incidence (8.9%) of invasive aspergillosis at our centre. This finding triggered the introduction of targeted antimould prophylaxis for patients with acute leukemia who were undergoing remission-induction chemotherapy.
Authors: Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson Journal: Clin Infect Dis Date: 2008-02-01 Impact factor: 9.079
Authors: Johan Maertens; Koen Theunissen; Gregor Verhoef; Johnny Verschakelen; Katrien Lagrou; Eric Verbeken; Alexander Wilmer; Jan Verhaegen; Marc Boogaerts; Johan Van Eldere Journal: Clin Infect Dis Date: 2005-09-29 Impact factor: 9.079
Authors: Me-Linh Luong; Charles Filion; Annie-Claude Labbé; Jean Roy; Jacques Pépin; Julia Cadrin-Tourigny; Stéphane Carignan; Donald C Sheppard; Michel Laverdière Journal: Diagn Microbiol Infect Dis Date: 2010-10 Impact factor: 2.803
Authors: S Perkhofer; C Lass-Flörl; M Hell; G Russ; R Krause; M Hönigl; C Geltner; J Auberger; G Gastl; M Mitterbauer; B Willinger; P Knöbl; G Resch; R Waldner; A Makrai; G Hartmann; M Girschikofsky; R Greil Journal: Int J Antimicrob Agents Date: 2010-10-13 Impact factor: 5.283
Authors: J J Vehreschild; M J G T Rüping; H Wisplinghoff; F Farowski; A Steinbach; R Sims; A Stollorz; K-A Kreuzer; M Hallek; C Bangard; O A Cornely Journal: J Antimicrob Chemother Date: 2010-04-21 Impact factor: 5.790
Authors: M Nucci; M Garnica; A B Gloria; D S Lehugeur; V C H Dias; L C Palma; P Cappellano; K Y Fertrin; F Carlesse; B Simões; M D Bergamasco; C A Cunha; A Seber; M P D Ribeiro; F Queiroz-Telles; M L M Lee; M L Chauffaille; L Silla; C A de Souza; A L Colombo Journal: Clin Microbiol Infect Date: 2012-09-25 Impact factor: 8.067
Authors: Mariska M Leeflang; Yvette J Debets-Ossenkopp; Caroline E Visser; Rob J P M Scholten; Lotty Hooft; Henk A Bijlmer; Johannes B Reitsma; Patrick Mm Bossuyt; Christina M Vandenbroucke-Grauls Journal: Cochrane Database Syst Rev Date: 2008-10-08
Authors: Amir A Tahami Monfared; Amy K O'Sullivan; Coleman Rotstein; George Papadopoulos Journal: Can J Infect Dis Med Microbiol Date: 2012 Impact factor: 2.471
Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079